|
1
|
Gwee KA, Gonlachanvit S, Ghoshal UC, Chua
ASB, Miwa H, Wu J, Bak YT, Lee OY, Lu CL, Park H, et al: Second
Asian consensus on irritable bowel syndrome. J Neurogastroenterol
Motil. 25:343–362. 2019. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Quigley EM, Abdel-Hamid H, Barbara G,
Bhatia SJ, Boeckxstaens G, De Giorgio R, Delvaux M, Drossman DA,
Foxx-Orenstein AE, Guarner F, et al: A global perspective on
irritable bowel syndrome: A consensus statement of the world
gastroenterology organisation summit task force on irritable bowel
syndrome. J Clin Gastroenterol. 46:356–366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kanazawa M, Hongo M and Fukudo S: Visceral
hypersensitivity in irritable bowel syndrome. J Gastroenterol
Hepatol. 26 (Suppl 3):S119–S121. 2011. View Article : Google Scholar
|
|
4
|
Carrasco-Labra A, Lytvyn L, Falck-Ytter Y,
Surawicz CM and Chey WD: AGA technical review on the evaluation of
functional diarrhea and diarrhea-predominant irritable bowel
syndrome in adults (IBS-D). Gastroenterology. 157:859–880. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hellström PM, Hein J, Bytzer P, Björnssön
E, Kristensen J and Schambye H: Clinical trial: The glucagon-like
peptide-1 analogue ROSE-010 for management of acute pain in
patients with irritable bowel syndrome: A randomized,
placebo-controlled, double-blind study. Aliment Pharmacol Ther.
29:198–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nozu T, Miyagishi S, Kumei S, Nozu R,
Takakusaki K and Okumura T: Glucagon-like peptide-1 analog,
liraglutide, improves visceral sensation and gut permeability in
rats. J Gastroenterol Hepatol. 33:232–239. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Smith NK, Hackett TA, Galli A and Flynn
CR: GLP-1: Molecular mechanisms and outcomes of a complex signaling
system. Neurochem Int. 128:94–105. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hellström PM: GLP-1 playing the role of a
gut regulatory compound. Acta Physiol (Oxf). 201:151–156. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smits MM, Tonneijck L, Muskiet MH, Kramer
MH, Cahen DL and van Raalte DH: Gastrointestinal actions of
glucagon-like peptide-1-based therapies: Glycaemic control beyond
the pancreas. Diabetes Obes Metab. 18:224–235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Y, Cui X, Chen Y, Wang Y, Li X, Lin L
and Zhang H: Exendin-4, an analogue of glucagon-like peptide-1,
attenuates hyperalgesia through serotonergic pathways in rats with
neonatal colonic sensitivity. J Physiol Pharmacol. 65:349–357.
2014.PubMed/NCBI
|
|
11
|
Hellström PM, Smithson A, Stowell G,
Greene S, Kenny E, Damico C, Leone-Bay A, Baughman R, Grant M and
Richardson P: Receptor-mediated inhibition of small bowel migrating
complex by GLP-1 analog ROSE-010 delivered via pulmonary and
systemic routes in the conscious rat. Regul Pept. 179:71–76. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei Y and Mojsov S: Distribution of GLP-1
and PACAP receptors in human tissues. Acta Physiol Scand.
157:355–357. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiao YF, Nikolskaya A, Jaye DA and Sigg
DC: Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents
via activation of the cAMP-dependent protein kinase A pathway.
Cardiovasc Diabetol. 10:62011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morikawa O, Sakai N, Obara H and Saito N:
Effects of interferon-alpha, interferon-gamma and cAMP on the
transcriptional regulation of the serotonin transporter. Eur J
Pharmacol. 349:317–324. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rumajogee P, Madeira A, Vergé D, Hamon M
and Miquel MC: Up-regulation of the neuronal serotoninergic
phenotype in vitro: BDNF and cAMP share Trk B-dependent mechanisms.
J Neurochem. 83:1525–1528. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kerckhoffs AP, ter Linde JJ, Akkermans LM
and Samsom M: SERT and TPH-1 mRNA expression are reduced in
irritable bowel syndrome patients regardless of visceral
sensitivity state in large intestine. Am J Physiol Gastrointest
Liver Physiol. 302:G1053–G1060. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
El-Salhy M, Wendelbo I and Gundersen D:
Serotonin and serotonin transporter in the rectum of patients with
irritable bowel disease. Mol Med Rep. 8:451–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wade PR, Chen J, Jaffe B, Kassem IS,
Blakely RD and Gershon MD: Localization and function of a 5-HT
transporter in crypt epithelia of the gastrointestinal tract. J
Neurosci. 16:2352–2364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miwa J, Echizen H, Matsueda K and Umeda N:
Patients with constipation-predominant irritable bowel syndrome
(IBS) may have elevated serotonin concentrations in colonic mucosa
as compared with diarrhea-predominant patients and subjects with
normal bowel habits. Digestion. 63:188–194. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bertrand PP and Bertrand RL: Serotonin
release and uptake in the gastrointestinal tract. Auton Neurosci.
153:47–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grundy D: 5-HT system in the gut: Roles in
the regulation of visceral sensitivity and motor functions. Eur Rev
Med Pharmacol Sci. 12 (Suppl 1):S63–S67. 2008.
|
|
22
|
Salaga M, Binienda A, Tichkule RB, Thakur
GA, Makriyannis A, Storr M and Fichna J: The novel peripherally
active cannabinoid type 1 and serotonin type 3 receptor agonist
AM9405 inhibits gastrointestinal motility and reduces abdominal
pain in mouse models mimicking irritable bowel syndrome. Eur J
Pharmacol. 836:34–43. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Y, Li Z, Yang Y, Lin L and Zhang H:
Role of glucagon-like peptide-1 in the pathogenesis of experimental
irritable bowel syndrome rat models. Int J Mol Med. 31:607–613.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Z, Zhang M, Zhou T, Shen Q and Qin X:
Exendin-4 promotes the vascular smooth muscle cell
re-differentiation through AMPK/SIRT1/FOXO3a signaling pathways.
Atherosclerosis. 276:58–66. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Franzellitti S and Fabbri E: Cyclic-AMP
mediated regulation of ABCB mRNA expression in mussel haemocytes.
PLoS One. 8:e616342013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smith PK, Krohn RI, Hermanson GT, Mallia
AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and
Klenk DC: Measurement of protein using bicinchoninic acid. Anal
Biochem. 150:76–85. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Camilleri M: Serotonergic modulation of
visceral sensation: Lower gut. Gut. 51 (Suppl 1):i81–i86. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matheus N, Mendoza C, Iceta R, Mesonero JE
and Alcalde AI: Melatonin inhibits serotonin transporter activity
in intestinal epithelial cells. J Pineal Res. 48:332–339. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Coates MD, Mahoney CR, Linden DR, Sampson
JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM
and Moses PL: Molecular defects in mucosal serotonin content and
decreased serotonin reuptake transporter in ulcerative colitis and
irritable bowel syndrome. Gastroenterology. 126:1657–1664. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gill RK, Anbazhagan AN, Esmaili A, Kumar
A, Nazir S, Malakooti J, Alrefai WA and Saksena S: Epidermal growth
factor upregulates serotonin transporter in human intestinal
epithelial cells via transcriptional mechanisms. Am J Physiol
Gastrointest Liver Physiol. 300:G627–G636. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ramamoorthy S, Cool DR, Mahesh VB, Leibach
FH, Melikian HE, Blakely RD and Ganapathy V: Regulation of the
human serotonin transporter. Cholera toxin-induced stimulation of
serotonin uptake in human placental choriocarcinoma cells is
accompanied by increased serotonin transporter mRNA levels and
serotonin transporter-specific ligand binding. J Biol Chem.
268:21626–21631. 1993.PubMed/NCBI
|
|
33
|
Cui XF, Zhou WM, Yang Y, Zhou J, Li XL,
Lin L and Zhang HJ: Epidermal growth factor upregulates serotonin
transporter and its association with visceral hypersensitivity in
irritable bowel syndrome. World J Gastroenterol. 20:13521–13529.
2014. View Article : Google Scholar : PubMed/NCBI
|
